The proposed model can reduce interobserver variability in BI-RADS density assessment, thereby providing more standard and consistent density assessment for use in decisions about supplemental screening and risk assessment.
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Bob, Follicular Lymphoma Survivor Bob took reasonable care of himself in his late 40’s. He swam every other day, played softball, played racquetball, and
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused…
Kureshi and Dougan discuss the roles of cytokines in the tumor microenvironment. Although there is a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways…
Fred Hutch Cancer Center scientists developed an engineered antibody that may be able to target immune cells capable of producing a protective response against RSV.…
China’s health regulator gave conditional approval to Platinum Life Excellence Biotech Co. Ltd.’s amimestrocel injection (hUC-MSC PLEB-001, Ruibosheng) as the nation’s first human umbilical cord-derived…
The hallmark of a good AI model is its ability to work the same in different groups, settings, and situations. See how these NCI researchers…
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment.
Karen Geboes, MD, PhD, UZ Gent – University Hospital Ghent, Ghent, Belgium, emphasizes the need for higher cure rates in patients with resectable pancreatic cancers.…
